Skip to main content
OpenTrials

Clinical trial condition

Urinary Bladder Neoplasms

Explore clinical trials studying Urinary Bladder Neoplasms. Study availability and eligibility vary by location and protocol.

1,199 public trials 263 recruiting studies
Refine in advanced search Browse all conditions

Urinary Bladder Neoplasms trial results

Active, Not Recruiting

Modern Immunotherapy in BCG-Unresponsive, BCG-Relapsing and High Risk BCG-Naive Non-Muscle Invasive Urothelial Carcinoma of the Bladder

NCT03317158

Conditions
Bladder Cancer, Carcinoma, Carcinoma, Transitional Cell, +15 more
Locations
  • BCG Oncology Phoenix, Arizona, United States
  • Indiana University Melvin and Bren Simon Cancer Center Indianapolis, Indiana, United States
  • University of Iowa Hospitals and Clinics Iowa City, Iowa, United States
  • Johns Hopkins University: Sidney Kimmel Comprehensive Cancer Center Baltimore, Maryland, United States
View Trial Details
Active, Not Recruiting

Stage II-IIIa Urothelial Cancer Randomizing Pre-operative Nivolumab With or Without Relatlimab

NCT06237920

Conditions
Antineoplastics Toxicity, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, +10 more
Locations
  • Rijnstate Arnhem, Gelderland, Netherlands
  • Radboud University Medical Center Nijmegen, Gelderland, Netherlands
  • NKI-AVL Amsterdam, North Holland, Netherlands
  • Amsterdam UMC (AUMC) Amsterdam, North Holland, Netherlands
View Trial Details
Active, Not Recruiting

Chemoradiotherapy With or Without Atezolizumab in Treating Patients With Localized Muscle Invasive Bladder Cancer

NCT03775265

Conditions
Bladder Urothelial Carcinoma, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, +12 more
Locations
  • Mayo Clinic Hospital in Arizona Phoenix, Arizona, United States
  • Mayo Clinic in Arizona Scottsdale, Arizona, United States
  • Banner University Medical Center - Tucson Tucson, Arizona, United States
  • University of Arizona Cancer Center-North Campus Tucson, Arizona, United States
View all 366 locations
View Trial Details
Active, Not Recruiting

A Study of TAR-200 in Combination With Cetrelimab Versus Concurrent Chemoradiotherapy in Participants With Muscle-invasive Bladder Cancer (MIBC) of the Bladder

NCT04658862

Conditions
Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Male Urogenital Diseases, +8 more
Locations
  • Loma Linda Univ Faculty Medic Loma Linda, California, United States
  • University of Southern California Los Angeles, California, United States
  • Providence Saint John s Health Center Santa Monica, California, United States
  • Stanford University Medical Center Stanford, California, United States
View all 290 locations
View Trial Details
Active, Not Recruiting

A Study of TAR-200 in Combination With Cetrelimab or TAR-200 Alone Versus Intravesical Bacillus Calmette-Guérin (BCG) in Participants With BCG-naïve High-risk Non-muscle Invasive Bladder Cancer (HR-NMIBC)

NCT05714202

Conditions
Bladder Cancer, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, +9 more
Locations
  • Mayo Clinic Scottsdale, Arizona, United States
  • Arkansas Urology Little Rock, Arkansas, United States
  • VA Long Beach Health Care System Long Beach, California, United States
  • Genesis Research, LLC - West Coast Urology Los Alamitos, California, United States
View all 240 locations
View Trial Details
Active, Not Recruiting

Comparing the New Anti-cancer Drug Eribulin With Chemotherapy Against the Usual Chemotherapy Alone in Metastatic Urothelial Cancer

NCT04579224

Conditions
Carcinoma, Carcinoma, Transitional Cell, Female Urogenital Diseases, +17 more
Locations
  • Kingman Regional Medical Center Kingman, Arizona, United States
  • Cancer Center at Saint Joseph's Phoenix, Arizona, United States
  • Mercy Hospital Fort Smith Fort Smith, Arkansas, United States
  • CHI Saint Vincent Cancer Center Hot Springs Hot Springs, Arkansas, United States
View all 449 locations
View Trial Details

Related conditions